Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on enzymatic, non-surgical therapies for tissue repair, and its news flow reflects this specialization. Company announcements frequently highlight clinical progress for its late-stage investigational product EscharEx®, including updates on the global VALUE Phase III trial in venous leg ulcers and planned studies in diabetic foot ulcers and pressure ulcers. Investors and healthcare professionals can follow how these trials evolve, along with peer-reviewed publications that analyze wound bed preparation and healing outcomes.
News about MediWound also covers the commercial and clinical use of its FDA-approved biologic NexoBrid®, indicated for enzymatic removal of eschar in thermal burns. Recent releases have described new clinical data on NexoBrid in traumatic tattoos from abrasion and blast injuries, as well as its role in scientific presentations at major burn congresses. Regulatory milestones, such as marketing approval in Australia and expansion to 45 countries, feature prominently in the company’s updates.
Operational and financial developments are another key theme in MDWD news. MediWound reports on expansion and commissioning of its GMP manufacturing facility in Yavne, Israel, designed to increase NexoBrid production capacity, and on BARDA- and U.S. Department of Defense-funded projects, including work on a room temperature-stable formulation. Quarterly and annual financial results, equity financings under shelf registration statements, and revenue guidance are detailed in regular press releases and associated conference calls.
For readers tracking MDWD, this news stream offers insight into clinical trial milestones, regulatory decisions, manufacturing readiness, government-supported programs, and financial performance. Bookmark this page to follow ongoing developments that shape MediWound’s burn and chronic wound therapy portfolio.
MediWound (Nasdaq: MDWD) will report its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026. Management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss results and business highlights.
Dial-in numbers and a live webcast link are provided, and an archived replay will be available on the company's Investors website.
MediWound (Nasdaq: MDWD) said its management will present at two upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences on Feb 26, 2026 at 10:40 a.m. ET (virtual), and TD Cowen 46th Annual Health Care on Mar 2, 2026 at 1:10 p.m. ET in Boston.
Webcasts and replays will be available via each conference website and through the Events & Presentations section of MediWound’s Investor Relations site.
MediWound (Nasdaq: MDWD) provided a corporate update ahead of the J.P. Morgan Healthcare Conference outlining clinical and operational progress and updated financial outlooks. Key points: EscharEx VALUE Phase III enrollment targets 216 patients across ~40 U.S./EU sites with an interim assessment and enrollment completion expected by year-end 2026; Phase II in diabetic foot ulcers planned for H2 2026 and an investigator-initiated pressure‑ulcer study planned for mid‑2026. The expanded NexoBrid facility is fully operational with a sixfold capacity increase; regulatory approvals are targeted in 2026. Fiscal highlights: 2025 revenue $17M, cash $54M, no debt, and updated revenue guidance of $24–26M (2026), $32–35M (2027), and $50–55M (2028).
MediWound (Nasdaq: MDWD) announced peer-reviewed prospective clinical data showing NexoBrid substantially reduces embedded particles that cause traumatic tattoos after abrasion and blast injuries.
In a 15-patient study at Sheba Medical Center, mean pigmented wound area fell from 37.5% post-scrubbing to 2.1% after NexoBrid, a 92.5% reduction. Removal rates were 96% for abrasive injuries and 84% for explosive injuries. Treatments were bedside, well tolerated, and reported no treatment-related adverse events in the early post-procedure period.
MediWound (Nasdaq: MDWD) reported third quarter 2025 results and a corporate update on November 20, 2025. Q3 revenue was $5.4M, up 23% year-over-year, with gross profit of $0.9M (16.5%). The company completed commissioning of an expanded NexoBrid manufacturing facility, targeting full operational capacity by year-end 2025 and a sixfold production increase. VALUE Phase III enrollment for EscharEx targets 216 patients across ~40 sites; a pre-specified interim assessment is planned after 65% complete treatment. MediWound raised $30M in equity and held $60M in cash as of Sept 30, 2025. Q3 net loss was $2.7M (EPS -$0.24); Adjusted EBITDA loss was $5.4M.
MediWound (Nasdaq: MDWD) will release third quarter 2025 financial results for the period ended September 30, 2025 on Thursday, November 20, 2025. Management will host a conference call and live webcast at 8:30 a.m. Eastern Time the same day to discuss results and provide a corporate update.
Dial-in numbers available include toll-free 1-844-676-8833, Israel 1-809-212373, and international 1-412-634-6869. A webcast link will be provided and an archived replay will be available on the company’s Investors website.
MediWound (Nasdaq: MDWD) completed commissioning of its expanded GMP manufacturing facility in Yavne, Israel on November 3, 2025, marking a step toward full operational readiness by year-end 2025. The expansion is expected to increase NexoBrid production capacity by approximately sixfold, aiming to support supply across more than 40 approved markets. The company says the facility will enable a scalable, reliable global supply once regulatory reviews are complete. Market availability remains subject to the completion of those regulatory reviews.
MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced a $30 million registered direct offering of ordinary shares. The company will sell 1,734,105 ordinary shares at $17.30 per share to a prominent U.S.-based mutual fund and healthcare-focused investors.
The offering is expected to close around September 30, 2025, with H.C. Wainwright & Co. serving as the exclusive placement agent. The proceeds will support EscharEx's pre-commercial activities, enhance manufacturing capabilities, and fund general corporate purposes. The offering is made through the company's shelf registration statement on Form F-3.
MediWound (Nasdaq: MDWD) has received marketing authorization from Australia's Therapeutic Goods Administration (TGA) for NexoBrid®, its enzymatic therapy for eschar removal in adult and pediatric burn patients. This approval expands NexoBrid's global presence to 45 countries.
The company's exclusive partner, Balance Medical, plans to launch NexoBrid commercially in Q4 2025. MediWound's manufacturing expansion, scheduled for completion by year-end 2025, will support the Australian launch and growing global demand. The approval represents a strategic entry point into the broader Asia-Pacific market.
MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, announced that its burn debridement therapy NexoBrid® will be featured in 36 scientific presentations at the 21st European Burns Association Congress in Berlin (September 3-6, 2025).
The presentations will showcase data demonstrating NexoBrid's benefits in various patient populations, including pediatric, elderly, and critically burned patients. Key findings highlight improvements in survival, recovery, and scar outcomes, along with advantages in infection control and inflammatory response modulation. Studies also demonstrate NexoBrid's superiority over surgical excision in both routine care and mass casualty scenarios.